Difference between revisions of "Caplacizumab (Cablivi)"
Jump to navigation
Jump to search
m (Jwarner moved page Caplacizumab to Caplacizumab (ALX-0081)) |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
Line 7: | Line 7: | ||
# Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. [http://www.nejm.org/doi/full/10.1056/NEJMoa1505533 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26863353 PubMed] | # Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. [http://www.nejm.org/doi/full/10.1056/NEJMoa1505533 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26863353 PubMed] | ||
− | [[Category: | + | [[Category:Drugs]] |
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
[[Category:Anti-vWF medications]] | [[Category:Anti-vWF medications]] |
Revision as of 22:52, 13 June 2018
Mechanism of action
A single domain antibody directed against the A1 domain of von Willebrand factor (vWF).
Preliminary data
Thrombotic thrombocytopenic purpura
- Peyvandi F, Scully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni A, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichts H, Duby C, Tersago D; TITAN Investigators. Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura. N Engl J Med. 2016 Feb 11;374(6):511-522. link to original article PubMed